The latest news......
EMA starts Review Tavneos®
The current review is a so called Article 20 non-pharmacovigilance procedure, initiated at the request of the European Commission. This type of procedure is used when questions arise about the scientific basis or robustness of the data that supported the original approval of a medicine.
In the case of Tavneos, concerns have been raised about how certain data from the main clinical study were collected, analysed, or reported. As a result, the EMA has been asked to re-examine all available evidence to confirm whether the original conclusions remain valid.
Review Patient Summit 2025
In November, patients, caregivers, clinicians and researchers from more than a dozen European countries met in Prague for the 2025 European Vasculitis Patient Summit.
Challenges in the diagnosis, classification and prognosis of ANCA-associated vasculitis.
A landmark review in Nature Reviews Rheumatology calls for a new, integrated approach to ANCA-associated vasculitis.When diagnosis, classification, biomarkers and patient experience come together, care becomes truly personal — and outcomes improve.
patients
Find Patient Advocacy Groups (VPAGs)
hospitals
Find vasculitis expertise
projects
Find out about the projects we are working on.